Lysophosphatidic	O
acid	O
downregulates	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
,	O
which	O
are	O
negatively	O
involved	O
in	O
lysophosphatidic	O
acid	O
-	O
induced	O
cell	B-Cell
invasion	O
.	O

Ovarian	B-Cancer
cancer	I-Cancer
is	O
a	O
highly	O
metastatic	O
disease	O
.	O

Lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
levels	O
are	O
elevated	O
in	O
ascites	B-Organism_substance
from	O
ovarian	B-Cancer
cancer	I-Cancer
patients	O
,	O
but	O
its	O
potential	O
role	O
in	O
ovarian	B-Cancer
cancer	I-Cancer
metastasis	O
has	O
just	O
begun	O
to	O
be	O
revealed	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
LPA	O
stimulates	O
invasion	O
of	O
primary	B-Cell
ovarian	I-Cell
cancer	I-Cell
cells	I-Cell
,	O
but	O
not	O
ovarian	B-Cell
epithelial	I-Cell
or	O
borderline	B-Cell
ovarian	I-Cell
tumor	I-Cell
cells	I-Cell
,	O
although	O
these	O
benign	B-Cell
cells	I-Cell
indeed	O
respond	O
to	O
LPA	O
in	O
cell	B-Cell
migration	O
.	O

We	O
have	O
found	O
that	O
LPA	O
downregulates	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMPs	O
)	O
.	O

TIMP2	O
and	O
TIMP3	O
play	O
functional	O
role	O
in	O
LPA	O
-	O
induced	O
invasion	O
as	O
negative	O
regulators	O
.	O

G	O
(	O
i	O
)	O
protein	O
,	O
phosphatidylinositol	O
-	O
3	O
kinase	O
(	O
PI3K	O
)	O
,	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
,	O
cytosolic	B-Organism_substance
phospholipase	O
A	O
(	O
2	O
)	O
and	O
urokinase	O
type	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
are	O
required	O
for	O
LPA	O
-	O
induced	O
cells	B-Cell
invasion	O
.	O

TIMP3	O
may	O
affect	O
two	O
independent	O
downstream	O
targets	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
and	O
p38	O
MAPK	O
.	O

In	O
vivo	O
,	O
LPA	O
stimulates	O
tumor	B-Cancer
metastasis	O
in	O
an	O
orthotopic	O
ovarian	B-Cancer
tumor	I-Cancer
model	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
a	O
PI3K	O
inhibitor	O
,	O
LY294002	O
.	O

In	O
summary	O
,	O
LPA	O
is	O
likely	O
a	O
key	O
component	O
for	O
promoting	O
ovarian	B-Organ
metastasis	O
in	O
vivo	O
.	O

LPA	O
downregulates	O
TIMP3	O
,	O
which	O
may	O
have	O
targets	O
other	O
than	O
metalloproteinases	O
.	O

Our	O
in	O
vivo	O
metastasis	O
mouse	O
model	O
is	O
useful	O
for	O
studying	O
the	O
efficacy	O
of	O
therapeutic	O
regimes	O
of	O
ovarian	B-Cancer
cancer	I-Cancer
.	O

